PTC Therapeutics, Inc.
2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
Last updated:
Abstract:
Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of .alpha.-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.
Status:
Application
Type:
Utility
Filling date:
10 Nov 2021
Issue date:
7 Apr 2022